Literature DB >> 3039344

An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes.

D Liebowitz, R Kopan, E Fuchs, J Sample, E Kieff.   

Abstract

The Epstein-Barr virus (EBV) latent infection membrane protein (LMP) is likely to be an important mediator of EBV-induced cell proliferation, since it is one of the few proteins encoded by the virus in latent infection and since production of this protein in Rat-1 cells results in their conversion to a fully transformed phenotype. LMP was previously noted to localize to patches at the cell periphery. In this paper we examine the basis of LMP patching in EBV-infected, transformed lymphocytes. Our data indicate that LMP is associated with the cytoskeletal protein vimentin. Although LMP is fully soluble in isotonic Triton X-100 buffer, only 50% of it is extracted from cells in this solution. The rest remains bound to the cytoskeleton. LMP undergoes phosphorylation, and phosphorylated LMP is preferentially associated with the cytoskeleton. As judged by both immunofluorescence and immunoelectron microscopy, the vimentin network in EBV-transformed lymphocytes or EBV-infected Burkitt tumor lymphocytes is abnormal. Vimentin and LMP often colocalize in a single patch near the plasma membrane. In response to Colcemid treatment of EBV-infected cells, vimentin reorganizes into perinuclear rings, as it does in uninfected cells. LMP is associated with these perinuclear rings. Vimentin (or a vimentin-associated protein) may be a transducer of an LMP transmembrane effect in lymphoproliferation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3039344      PMCID: PMC365360          DOI: 10.1128/mcb.7.7.2299-2308.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  24 in total

1.  Widespread occurrence of intermediate-sized filaments of the vimentin-type in cultured cells from diverse vertebrates.

Authors:  W W Franke; E Schmid; S Winter; M Osborn; K Weber
Journal:  Exp Cell Res       Date:  1979-10-01       Impact factor: 3.905

2.  Amino acid sequence characterization of mammalian vimentin, the mesenchymal intermediate filament protein.

Authors:  N Geisler; U Plessmann; K Weber
Journal:  FEBS Lett       Date:  1983-10-31       Impact factor: 4.124

3.  Differences in the behavior of the membrane and membrane-associated filamentous structures in normal and chronic lymphocytic leukemia (CLL) lymphocytes.

Authors:  D Zucker-Franklin; L F Liebes; R Silber
Journal:  J Immunol       Date:  1979-01       Impact factor: 5.422

4.  Gene product of v-fgr onc: hybrid protein containing a portion of actin and a tyrosine-specific protein kinase.

Authors:  G Naharro; K C Robbins; E P Reddy
Journal:  Science       Date:  1984-01-06       Impact factor: 47.728

5.  Characterization of an antigen whose cell surface expression is induced by infection with Epstein-Barr virus.

Authors:  B Sugden; S Metzenberg
Journal:  J Virol       Date:  1983-06       Impact factor: 5.103

6.  Primary and secondary structure of hamster vimentin predicted from the nucleotide sequence.

Authors:  Y E Quax-Jeuken; W J Quax; H Bloemendal
Journal:  Proc Natl Acad Sci U S A       Date:  1983-06       Impact factor: 11.205

7.  Ligand-induced association of surface immunoglobulin with the detergent-insoluble cytoskeletal matrix of the B lymphocyte.

Authors:  J Braun; P S Hochman; E R Unanue
Journal:  J Immunol       Date:  1982-03       Impact factor: 5.422

8.  Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein.

Authors:  S Fennewald; V van Santen; E Kieff
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

9.  A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection.

Authors:  K Hennessy; S Fennewald; M Hummel; T Cole; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

10.  Abnormal expression of vimentin intermediate filaments in human lymphoid cell lines with deletion or translocation of the distal end of chromosome 8.

Authors:  K Dellagi; J C Brouet; M M Portier; G M Lenoir
Journal:  J Natl Cancer Inst       Date:  1984-07       Impact factor: 13.506

View more
  45 in total

1.  The late lytic LMP-1 protein of Epstein-Barr virus can negatively regulate LMP-1 signaling.

Authors:  K D Erickson; J M Martin
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Authors:  Jingwu Xu; Ali Ahmad; José Menezes
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

3.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

4.  Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells.

Authors:  D Liebowitz; J Mannick; K Takada; E Kieff
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

5.  The Epstein-Barr virus BNLF-1 membrane protein LMP1 induces homotypic adhesion mediated by CD11a/CD18 in a murine B-cell line, mimicking the action of phorbol ester.

Authors:  R Salcedo; S M Fuerstenberg; M Patarroyo; G Winberg
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

Review 6.  Molecular basis for Epstein-Barr virus induced pathogenesis and disease.

Authors:  C Sample; E Kieff
Journal:  Springer Semin Immunopathol       Date:  1991

7.  The Epstein-Barr virus-encoded LMP-1 oncoprotein negatively affects Tyk2 phosphorylation and interferon signaling in human B cells.

Authors:  Timothy R Geiger; Jennifer M Martin
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

8.  Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases.

Authors:  N M Jiwa; J J Oudejans; D F Dukers; W Vos; A Horstman; P van der Valk; J M Middledorp; J M Walboomers; C J Meijer
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

Review 9.  Epstein-Barr virus, infectious mononucleosis, and posttransplant lymphoproliferative disorders.

Authors:  M A Nalesnik; T E Starzl
Journal:  Transplant Sci       Date:  1994-09

10.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.